Guideline / position statementindependent cross-checkabstract checked★ key study I-BAR-114 in-depth review
International society statement on endoscopy and Barrett
International Federation for Surgery for Obesity and Metabolic Disorders Position Statement on the role of Upper Gastrointestinal Endoscopy Before and After Metabolic Bariatric Surgery.
Overview
Brown et al.. Obes Surg 2025 · PMID 41108366 · DOI 10.1007/s11695-025-08206-8
Barrett changes were found in about 2.4 in 100 people after weight-loss surgery, but data were weak and short-term.
Does the study support the specific claim? Partly · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Guide endoscopy around surgery
- How was the study done?
Position statement with systematic review
- How many people, animals or samples were studied?
not stated
- What was actually found?
BE 2.4% after MBS
- How large was the observed effect?
Proportion
- What do the results mean in everyday life?
Barrett can occur; check with endoscopy when indicated
- What are the study's limitations?
Weak data
- What does it say about Elawady's specific claim?
Smaller risk than archive implies; not zero
- Do the results apply to Germany and Europe?
International
- What can explicitly not be concluded from this study?
Sleeve-specific long-term risk
Scientific in-depth review
1. Full reference
- Authors
- Brown et al.
- Journal
- Obes Surg
- Year
- 2025
- Identifier
- PMID 41108366 DOI 10.1007/s11695-025-08206-8
- Verification
- verified – PubMed efetch 2026-10-26 + Crossref API
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
COI statement (PubMed record): Declarations. Ethics Approval: Not relevant to this type of paper. Competing interests: WB reports: Grants from Johnson and Johnson, Medtronic, GORE, Applied Medical, Novo Nordisk, NHMRC, Myerton and the Australian Commonwealth Government. Personal fees from Johnson and Johnson, GORE, Novo Nordisk, Pfizer, Medtronic, Lily and Merck Sharpe and Dohme for lectures and advisory boards. The disclosure list was shortened here; the complete statement is in the original publication.
2. Research question
What is the role of upper GI endoscopy before and after metabolic bariatric surgery?
3. Study design and population
- Study design
- Guideline / position statement – IFSO position statement based on a systematic review (PRISMA, JBI appraisal)
- Population
People undergoing MBS
- Country
International
- Period
2025
- Sample size
not stated in abstract
- Inclusion and exclusion criteria
Systematic review of the literature
4. Methods and endpoints
- Exposure / intervention
MBS
- Comparator
not applicable
- Endpoints
Endoscopic findings, Barrett incidence
- Statistical methods
Pooled proportions with I2
5. Actual results
- Results
Abnormal findings on pre-MBS endoscopy 61% (55-67%); <1% had findings precluding MBS; 23% changed procedure. Post-operative incidence of Barrett after MBS 2.4% (1.66-3.45; I2 92.1%). Regression/progression of pre-existing BE poorly defined. Seven recommendations; data to be re-explored in 3 years.
- Absolute risks
Barrett after MBS about 2.4 in 100.
- Authors' conclusion
Heterogeneous data, high likelihood of bias and limited follow-up beyond 2 years; seven practice recommendations issued.
6. Strengths
- Current international society position
- Systematic review basis
7. Weaknesses
- Heterogeneous data, short follow-up
- Pooled across all MBS types
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Position statement; authors flag high likelihood of bias in source data. Lead author reports industry funding (PubMed COI).
9. Assessment of the statistical interpretation
Pooled 2.4% is lower than SG-specific pooled 5.6-8%; differences in follow-up and procedure mix.
10. Relevance to the specific claim
Gives a lower, society-level estimate of Barrett after surgery; relevant to the size of the risk in C-BAR-04.
11. Independent contrary findings
Not SG-specific; short follow-up.
12. Transferability to Germany and Europe
International.
13. Overall methodological judgement
Useful calibration; uncertainty acknowledged.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | not assessable |
| Precision of results | moderate |
| Directness | indirect |
| Reproducibility | unknown |
| Consistency with the overall evidence | mixed |
| Regional transferability | moderate |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Long-term BE incidence after SG.
15. Linked fact checks
- Sleeve gastrectomy leaves the oesophagus exposed to Barrett's oesophagus (archive: Barrett's in 4% at 10 years in SLEEVEPASS). – Studies with mixed or unclear results